CAJ | 학술논문

血栓性疾病的发病率极高，且具有很高的致残率和致死率，其预防和治疗主要针对抗血小板聚集、抗凝和溶栓等三个环节。抗血栓治疗方法的选择强调个体化原则。利伐沙班作为直接Ⅹa因子抑制剂，不需要抗凝血酶Ⅲ就能发挥其抗凝活性，且对凝血酶原复合物中的Ⅹa因子无效，可作为传统抗凝剂的替代抗凝药。本文就利伐沙班治疗症状性静脉血栓疾病、术后静脉血栓形成、心血管系统血栓形成等临床应用综述如下。
혈전성질병적발병솔겁고，차구유흔고적치잔솔화치사솔，기예방화치료주요침대항혈소판취집、항응화용전등삼개배절。항혈전치료방법적선택강조개체화원칙。리벌사반작위직접Ⅹa인자억제제，불수요항응혈매Ⅲ취능발휘기항응활성，차대응혈매원복합물중적Ⅹa인자무효，가작위전통항응제적체대항응약。본문취리벌사반치료증상성정맥혈전질병、술후정맥혈전형성、심혈관계통혈전형성등림상응용종술여하。
Incidence of thrombotic disease is very high, and this disease can result in high mortality and high disability rate. Prevention and treatment of the disease mainly include:antiplatelet, anticoagulation and thrombolysis. Choice of anti?thrombotic treatment based emphasizes on individuation. As a direct inhibitor of factor Xa, Rivaroxaban exert its anticoagu?lant activity without antithrombinⅢbut is ineffective to theⅩa in prothrombin complex, which can be used as a substitute of traditional anticoagulant. In this paper, applications of Rivaroxaban on treating symptomatic venous thromboembolic dis?ease, postoperative venous thrombosis and cardiovascular thrombosis are reviewed.